- Home
- EDSA vs RLYB Comparison
EDSA vs RLYB Comparison
Compare EDSA & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- RLYB
- Stock Information
- Founded
- EDSA 2015
- RLYB 2018
- Country
- EDSA Canada
- RLYB United States
- Employees
- EDSA N/A
- RLYB N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- RLYB Health Care
- Exchange
- EDSA Nasdaq
- RLYB Nasdaq
- Market Cap
- EDSA 13.8M
- RLYB 14.4M
- IPO Year
- EDSA N/A
- RLYB 2021
- Fundamental
- Price
- EDSA $2.18
- RLYB $0.42
- Analyst Decision
- EDSA Strong Buy
- RLYB Hold
- Analyst Count
- EDSA 2
- RLYB 3
- Target Price
- EDSA $13.00
- RLYB $15.00
- AVG Volume (30 Days)
- EDSA 22.9K
- RLYB 8.2M
- Earning Date
- EDSA 08-08-2025
- RLYB 08-07-2025
- Dividend Yield
- EDSA N/A
- RLYB N/A
- EPS Growth
- EDSA N/A
- RLYB N/A
- EPS
- EDSA N/A
- RLYB N/A
- Revenue
- EDSA N/A
- RLYB $848,000.00
- Revenue This Year
- EDSA N/A
- RLYB N/A
- Revenue Next Year
- EDSA N/A
- RLYB N/A
- P/E Ratio
- EDSA N/A
- RLYB N/A
- Revenue Growth
- EDSA N/A
- RLYB N/A
- 52 Week Low
- EDSA $1.55
- RLYB $0.22
- 52 Week High
- EDSA $5.59
- RLYB $1.54
- Technical
- Relative Strength Index (RSI)
- EDSA 60.86
- RLYB 56.74
- Support Level
- EDSA $1.89
- RLYB $0.36
- Resistance Level
- EDSA $2.23
- RLYB $0.45
- Average True Range (ATR)
- EDSA 0.11
- RLYB 0.05
- MACD
- EDSA 0.02
- RLYB 0.01
- Stochastic Oscillator
- EDSA 85.29
- RLYB 35.31
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.